<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00616655</url>
  </required_header>
  <id_info>
    <org_study_id>194-027</org_study_id>
    <nct_id>NCT00616655</nct_id>
  </id_info>
  <brief_title>Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects</brief_title>
  <official_title>A Double Blind, Randomized, Placebo Controlled, Multicenter Study Examining the Efficacy and Safety of SEP-225441 in Subjects With Generalized Anxiety Disorder.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and efficacy of SEP-225441 (eszopiclone) in subjects with generalized
      anxiety disorder (GAD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double blind, placebo controlled study of the safety and
      efficacy of SEP-225441 (eszopiclone) in male and female adult subjects with a diagnosis of
      generalized anxiety disorder (GAD). The study consists of a screening period of 7-10 days, 8
      weeks of treatment, and a 7 day follow-up period. This study was previously posted by
      Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and
      in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 8 in the Total Score on the Hamilton Anxiety Scale (HAM-A), as Assessed by the Site-trained Rater</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>THe HAM-M was administered by a site-trained rater and measured the severity of the subjects' anxiety symptoms using 14 items of the HAM-M rating scale. These items included: anxious mood, tension, fears, insomnia, intellectual, depressed mood, somatic complaints-muscular, somatic complaints-sensory, cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary symptoms, autonomic symptoms, and behavior at interview. All items are measured on a 5-point scale (0-4). The Ham-A total score can range from 0 to 56 with higher scores indicating higher severity of anxiety symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Hamilton Anxiety Scale (HAM-A) Total Score (Except for Week 8)</measure>
    <time_frame>Baseline, Weeks 2, 4, 6 based on last observation carried forward (LOCF)</time_frame>
    <description>The HAM-A was administered by a site-trained rater and measured the severity of the subjects' anxiety symptoms using 14 items of the HAM-A rating scale. These items included: anxious mood, tension, fears, insomnia, intellectual, depressed mood, somatic complaints-muscular, somatic complaints-sensory, cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary symptoms, autonomic symptoms, and behavior at interview. all items are measured on a 5-point scale (0-4). Ham-A total score can range from 0 to 56 with higher scores indicating higher severity of anxiety symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Individual Item Scores on HAM-A</measure>
    <time_frame>Baseline, Weeks 2, 4, 6, 8</time_frame>
    <description>The HAM-A was administered by a site trained rater and measured the severity of the subjects' anxiety symptoms using 14 items of the HAM-A rating scale. These items include: anxious mood, tension, fears, insomnia, intellectual, depressed mood, somatic complaints-muscular, somatic complaints-sensory, cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary symptoms, autonomic symptoms, and behavior at interview. All items are measured on a t5-point scale (0-4). Each HAM-A individual item score can range from 0 to 4 with higher scores indicating higher severity of anxiety questions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinician Global Impression of Severity (CGI-S)</measure>
    <time_frame>Baseline, Weeks 2, 4, 6, 8, based on last observation carried forward (LOCF)</time_frame>
    <description>The CGI-Swas completed by a board certified psychiatrist and represents the clinician's subjective assessment of severity of the subject's anxiety symptoms as assessed by a 7-scale score for a single question, &quot;Considering your total clinical experience with this particular population, how anxious is the subject at this time?&quot; The score was based on the following scale: 1=normal, not at all anxious; 2=borderline anxious; 3=mildly anxious; 4=moderately anxious; 5=markedly anxious; 6=severly anxious; 7=among the most extremely anxious subjects. CGI-S score can range from 0 to 7, with higher values indicating higher severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression- Improvement (CGI-I)</measure>
    <time_frame>Weeks 2, 4, 6, 8, and 9, based on last observation carried forward (LOCF)</time_frame>
    <description>CGI-I was completed by a board certified psychiatrist and represented the clinician's subjective assessment of improvement of the subject's anxiety symptoms based on the following question, &quot;Compared to his/her condition at Visit 2, how much has he/she changed?&quot; The score was based on the following scale: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse. CGI-I score can range from 0 to 7, with higher values indicating less improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Scale (HAM-A) 50% Anxiolytic Response</measure>
    <time_frame>Week 2, 4, 6, 8</time_frame>
    <description>The HAM-A was administered by a site-trained rater and measured the severity of the subjects' anxiety symptoms using 14 items of the HAM-A rating scale. These items include: anxious mood, tension, fears, insomnia, intellectual, depressed mood, somatic complaints-muscular, somatic complaints-sensory, cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary symptoms, autonomic symptoms, and behavior at interview. All items are measured on a 5-point scale (0-4). A 50% anxiolytic response was defined as a 50% or greater reduction from baseline in the HAM-A total score.
The Ham-A total score can range from 0 to 56 with higher scores indicating higher severity of anxiety symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Scale (HAM-A) Remission</measure>
    <time_frame>Week 2, 4, 6, 8 based on last observation carried forward (LOCF)</time_frame>
    <description>The HAM-A was administered by a site-trained rater and measured the severity of the subjects' anxiety symptoms using 14 items of the HAM-A rating scale. These items include: anxious mood, tension, fears, insomnia, intellectual, depressed mood, somatic complaints-muscular, somatic complaints-sensory, cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary symptoms, autonomic symptoms, and behavior at interview. All items are measured on a 5-point scale (0-4). Remission was defined as a HAM-A total score of 7 or less.
The Ham-A total score can range from 0 to 56 with higher scores indicating higher severity of anxiety symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Short Form</measure>
    <time_frame>Baseline, Weeks 2, 4, 6, 8, based on last observation carried forward (LOCF)</time_frame>
    <description>The Q-LES-Q was completed by the subject and assessed quaility of life based on 16 items, each evaluated on a 5-point scale of overall level of enjoyment/satisfaction: 1=very poor; 2=poor; 3=fair; 4=good; 5=very good. The overall percentage score was computed as a sum of items 1 to 14 as expressed as a percentage of the maximum possible score: Overall Percentage Score = Sum [item 1... item 14]-14)/(70-14 ) *100%. Q-LES-Q overall percentage score can range from 0 to 100, with higher values indicating higher quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Insomnia Severity Index (ISI) Total Score</measure>
    <time_frame>Baseline, Weeks 2, 4, 6, 8, based on lst observation carried forward (LOCF)</time_frame>
    <description>The ISI was completed by the subject and is an assessment of the severity of insomnia. The administered extended ISI questionnaire consists of 5 items (containing 7 questions, as item 1 contains 3 questions) comprising the original ISI questionnaire, plus 6 quality of life related items (sleep quality, restedness/refreshness upon arising, daytime fatigue, attention/concentration, relationships and mood disturbances), and 2 items assessing duration and frequency of sleep problems. All items, except for the insomnia duration and frequency questions, are measured on a Likert-type 5-point scale (0-4). ISI total score can range from 0 to 28, with higher scores indicating more severe insomnia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Sheehan Disability Scale (SDS)</measure>
    <time_frame>Baseline, Weeks 2, 4, 6, 8, based on last observation carried forward (LOCF)</time_frame>
    <description>The SDS was completed by the subject and captured the subject's level of disability. The subject rated the extent to which his or her work, social life or leisure activities, and home life or family responsibilities were impaired by his or her symptoms on a 10-point visual analog scale. SDS total score can range from 0 to 30, with higher scores indicating higher functional impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Epworth Sleepiness Scale (ESS)</measure>
    <time_frame>Baseline, Weeks 2, 4, 6, 8, based on last observation carried forward (LOCF)</time_frame>
    <description>ESS was completed by the subject and assessed daytime sedation based on 8 items, each presenting a situation for which the subject needed to evaluate how likely he/she is to doze off or fall asleep in contrast to feeling just tired. Each item was evaluated on the following scale: 0 = would never doze; 1 = slight chance of dozing; 2 = moderate chance of dozing; 3 = high chance of dozing. ESS total score can range from 0 to 24, with higher scores indicating higher levels of daytime sleepiness.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">456</enrollment>
  <condition>Generalized Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SEP-225441 (eszopiclone) total daily dose of 1.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SEP-225441 (eszopiclone) total daily dose of 0.9 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo total daily dose 0.9 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eszopiclone</intervention_name>
    <description>SEP-225441 (eszopiclone) total daily dose of 1.5 mg</description>
    <arm_group_label>1</arm_group_label>
    <other_name>SEP-225441</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eszopiclone</intervention_name>
    <description>SEP-225441 (eszopiclone) total daily dose of 0.9 mg</description>
    <arm_group_label>2</arm_group_label>
    <other_name>SEP-225441</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo total daily dose 0.9 mg</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects must be between 18 and 50 years of age

          -  Subjects must have GAD

          -  Subjects must be in otherwise good general health

        Exclusion Criteria:

          -  Subject has a documented history of HIV, hepatitis B or hepatitis C.

          -  Subject has a recent history (within 6 months of study entry) or current diagnosis of
             Major Depressive Disorder, panic disorder (or 3 or more panic attacks in the past
             month). Post Traumatic Stress Disorder, body dysmorphic disorder, eating disorder, or
             other disorder.

          -  Subject has a history or presence of Obsessive-Compulsive Disorder (OCD), any
             psychotic, bipolar or schizophrenic disorder.

          -  Subject has presence or history of antisocial personality or other severe disorder

          -  Subject has refractory GAD (previously unresponsive to 2 or more adequate courses of
             SSRI, SNRI, benzodiazepine or non-benzodiazepine treatment for GAD).

          -  Subject has history of seizures, including febrile seizures.

          -  Subject has initiated psychotherapeutic intervention with 30 days; however, continued
             psychotherapy is allowed if stable and not specifically directed at GAD.

          -  Subject is undergoing or has undergone electroconvulsive therapy.

          -  Subject is a current smoker or has smoked within the last 12 months.

          -  Subject has donated blood within the past 30 days or plans to donate during and within
             30 days after study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CNS Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sunovion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham Psychiatry Pharaceutical Studies, Inc.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwestern Research, Inc.</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwestern Research, Inc.</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Clinical Trials Medical Group</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California clinical Trials Medical Group</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Excell Research</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Clinical Trials Medical Group</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwestern Research, Inc.</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California clinical Trials Medical Group</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Universtiy Medical center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of CT Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Psychiatric Care, PC</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Clinical Research Center LLC</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarkis Clinical Trials</name>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive NeuroScience, Inc.</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stedman Clinical Trials, LLC</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Janus Center for Psychiatric Research</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive NeuroScience, Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carmen Research</name>
      <address>
        <city>Smyrna</city>
        <state>Georgia</state>
        <zip>30080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Center for Psychiatric Research</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60194</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive NeuroScience, Inc.</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince and Associats Clinical Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Technology, Inc.</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pedia Research, LLC</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharasite Research, Inc.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Research Associates, Inc.</name>
      <address>
        <city>Braintree</city>
        <state>Massachusetts</state>
        <zip>02184</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Emotional Fitness</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI Worldwide, LLC</name>
      <address>
        <city>Clementon</city>
        <state>New Jersey</state>
        <zip>08021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Social Psychiatry Research Institute</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurobehavioral Research, Inc.</name>
      <address>
        <city>Cedarhurst</city>
        <state>New York</state>
        <zip>11516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive NeuroScience, Inc.</name>
      <address>
        <city>Fresh Meadows</city>
        <state>New York</state>
        <zip>11366</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fieve Clinica Services, Inc.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical &amp; Behavioral Health Research, PC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical &amp; Behavioral Health Research, P.C.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond Behavioral Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenwood Psychiatric Associates, P.L.L.C.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizon Medical Services</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Coast Clinical Trials</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Patient Priority Clinical Sties, LLC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Star Mdical Research, LLC</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPS Research Company</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Center for Clinical Investigations, Inc.</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Center for Clinical Investigations, Inc.</name>
      <address>
        <city>Salem</city>
        <state>Oregon</state>
        <zip>97301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI Worldwide, LLC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>rhode Island Mood &amp; Memory Research Institute</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Future Search Trials</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolos Guerra, Jr., M.D.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Psychiatric Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grayline Clinical Drug Trials</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia, Center for Psychiatric Clinical Research</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2008</study_first_submitted>
  <study_first_submitted_qc>February 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2008</study_first_posted>
  <results_first_submitted>June 2, 2015</results_first_submitted>
  <results_first_submitted_qc>July 27, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 21, 2015</results_first_posted>
  <disposition_first_submitted>December 16, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>December 16, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 18, 2009</disposition_first_posted>
  <last_update_submitted>March 10, 2016</last_update_submitted>
  <last_update_submitted_qc>March 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anxiety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eszopiclone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Arm</title>
          <description>Placebo</description>
        </group>
        <group group_id="P2">
          <title>Eszopiclone Low Dose Arm</title>
          <description>SEP-225441 (eszopiclone) total daily dose of 0.9 mg</description>
        </group>
        <group group_id="P3">
          <title>Eszopiclone High Dose Arm</title>
          <description>SEP-225441 (eszopiclone) total daily dose of 1.5 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="153"/>
                <participants group_id="P3" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="112"/>
                <participants group_id="P3" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Does not meet in/ex criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT Population</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Arm</title>
          <description>Placebo</description>
        </group>
        <group group_id="B2">
          <title>Eszopiclone Low Dose Arm</title>
          <description>SEP-225441 (eszopiclone) total daily dose of 0.9 mg</description>
        </group>
        <group group_id="B3">
          <title>Eszopiclone High Dose Arm</title>
          <description>SEP-225441 (eszopiclone) total daily dose of 1.5 mg</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="149"/>
            <count group_id="B2" value="146"/>
            <count group_id="B3" value="145"/>
            <count group_id="B4" value="440"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="145"/>
                    <measurement group_id="B4" value="440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="145"/>
                    <measurement group_id="B4" value="440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 8 in the Total Score on the Hamilton Anxiety Scale (HAM-A), as Assessed by the Site-trained Rater</title>
        <description>THe HAM-M was administered by a site-trained rater and measured the severity of the subjects' anxiety symptoms using 14 items of the HAM-M rating scale. These items included: anxious mood, tension, fears, insomnia, intellectual, depressed mood, somatic complaints-muscular, somatic complaints-sensory, cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary symptoms, autonomic symptoms, and behavior at interview. All items are measured on a 5-point scale (0-4). The Ham-A total score can range from 0 to 56 with higher scores indicating higher severity of anxiety symptoms.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>ITT Population: /The ITT population will include all randomized subjects who received at least one does of study medication during the double-blind period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone Low Dose Arm</title>
            <description>SEP-225441 (eszopiclone) total daily dose of 0.9 mg</description>
          </group>
          <group group_id="O3">
            <title>Eszopiclone High Dose Arm</title>
            <description>SEP-225441 (eszopiclone) total daily dose of 1.5 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in the Total Score on the Hamilton Anxiety Scale (HAM-A), as Assessed by the Site-trained Rater</title>
          <description>THe HAM-M was administered by a site-trained rater and measured the severity of the subjects' anxiety symptoms using 14 items of the HAM-M rating scale. These items included: anxious mood, tension, fears, insomnia, intellectual, depressed mood, somatic complaints-muscular, somatic complaints-sensory, cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary symptoms, autonomic symptoms, and behavior at interview. All items are measured on a 5-point scale (0-4). The Ham-A total score can range from 0 to 56 with higher scores indicating higher severity of anxiety symptoms.</description>
          <population>ITT Population: /The ITT population will include all randomized subjects who received at least one does of study medication during the double-blind period.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="7.0"/>
                    <measurement group_id="O2" value="-9.3" spread="7.4"/>
                    <measurement group_id="O3" value="-9.5" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Hamilton Anxiety Scale (HAM-A) Total Score (Except for Week 8)</title>
        <description>The HAM-A was administered by a site-trained rater and measured the severity of the subjects' anxiety symptoms using 14 items of the HAM-A rating scale. These items included: anxious mood, tension, fears, insomnia, intellectual, depressed mood, somatic complaints-muscular, somatic complaints-sensory, cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary symptoms, autonomic symptoms, and behavior at interview. all items are measured on a 5-point scale (0-4). Ham-A total score can range from 0 to 56 with higher scores indicating higher severity of anxiety symptoms.</description>
        <time_frame>Baseline, Weeks 2, 4, 6 based on last observation carried forward (LOCF)</time_frame>
        <population>ITT Population: The ITT population will include all randomized subjects who received at least one dose of study medication during the double-blind period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone Low Dose Arm</title>
            <description>SEP-225441 (eszopiclone) total daily dose of 0.9 mg</description>
          </group>
          <group group_id="O3">
            <title>Eszopiclone High Dose Arm</title>
            <description>SEP-225441 (eszopiclone) total daily dose of 1.5 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Hamilton Anxiety Scale (HAM-A) Total Score (Except for Week 8)</title>
          <description>The HAM-A was administered by a site-trained rater and measured the severity of the subjects' anxiety symptoms using 14 items of the HAM-A rating scale. These items included: anxious mood, tension, fears, insomnia, intellectual, depressed mood, somatic complaints-muscular, somatic complaints-sensory, cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary symptoms, autonomic symptoms, and behavior at interview. all items are measured on a 5-point scale (0-4). Ham-A total score can range from 0 to 56 with higher scores indicating higher severity of anxiety symptoms.</description>
          <population>ITT Population: The ITT population will include all randomized subjects who received at least one dose of study medication during the double-blind period.</population>
          <units>unit on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2" spread="3.4"/>
                    <measurement group_id="O2" value="24.0" spread="3.4"/>
                    <measurement group_id="O3" value="24.0" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 - Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" spread="5.7"/>
                    <measurement group_id="O2" value="-4.8" spread="5.0"/>
                    <measurement group_id="O3" value="-6.0" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4-Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" spread="6.0"/>
                    <measurement group_id="O2" value="-7.6" spread="6.3"/>
                    <measurement group_id="O3" value="-8.0" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.9" spread="6.3"/>
                    <measurement group_id="O2" value="-8.7" spread="7.2"/>
                    <measurement group_id="O3" value="-8.5" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Individual Item Scores on HAM-A</title>
        <description>The HAM-A was administered by a site trained rater and measured the severity of the subjects' anxiety symptoms using 14 items of the HAM-A rating scale. These items include: anxious mood, tension, fears, insomnia, intellectual, depressed mood, somatic complaints-muscular, somatic complaints-sensory, cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary symptoms, autonomic symptoms, and behavior at interview. All items are measured on a t5-point scale (0-4). Each HAM-A individual item score can range from 0 to 4 with higher scores indicating higher severity of anxiety questions.</description>
        <time_frame>Baseline, Weeks 2, 4, 6, 8</time_frame>
        <population>ITT Population: The ITT population will include all randomized subjects who received at least one dose of study medication during the double-blind period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone Low Dose Arm</title>
            <description>SEP-225441 (eszopiclone) total daily dose of 0.9 mg</description>
          </group>
          <group group_id="O3">
            <title>Eszopiclone High Dose Arm</title>
            <description>SEP-225441 (eszopiclone) total daily dose of 1.5 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Individual Item Scores on HAM-A</title>
          <description>The HAM-A was administered by a site trained rater and measured the severity of the subjects' anxiety symptoms using 14 items of the HAM-A rating scale. These items include: anxious mood, tension, fears, insomnia, intellectual, depressed mood, somatic complaints-muscular, somatic complaints-sensory, cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary symptoms, autonomic symptoms, and behavior at interview. All items are measured on a t5-point scale (0-4). Each HAM-A individual item score can range from 0 to 4 with higher scores indicating higher severity of anxiety questions.</description>
          <population>ITT Population: The ITT population will include all randomized subjects who received at least one dose of study medication during the double-blind period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anxious Mood-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.5"/>
                    <measurement group_id="O2" value="2.8" spread="0.5"/>
                    <measurement group_id="O3" value="2.8" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxious Mood-Week 2 -Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.8"/>
                    <measurement group_id="O2" value="-0.5" spread="0.7"/>
                    <measurement group_id="O3" value="-0.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxious Mood-Week 4 - Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.9"/>
                    <measurement group_id="O2" value="-0.8" spread="0.8"/>
                    <measurement group_id="O3" value="-0.9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxious Mood-Week 6 - Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="0.9"/>
                    <measurement group_id="O2" value="-0.8" spread="0.8"/>
                    <measurement group_id="O3" value="-1.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxious Mood-Week 8- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="1.0"/>
                    <measurement group_id="O2" value="-0.9" spread="0.9"/>
                    <measurement group_id="O3" value="-1.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tension - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.5"/>
                    <measurement group_id="O2" value="2.6" spread="0.5"/>
                    <measurement group_id="O3" value="2.7" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tension - Week 2 -Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.9"/>
                    <measurement group_id="O2" value="-0.4" spread="0.7"/>
                    <measurement group_id="O3" value="-0.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tension - Week 4 - Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.0"/>
                    <measurement group_id="O2" value="-0.6" spread="0.9"/>
                    <measurement group_id="O3" value="-0.8" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tension - Week 6- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.0"/>
                    <measurement group_id="O2" value="-0.8" spread="1.0"/>
                    <measurement group_id="O3" value="-1.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tension - Week 8- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.0"/>
                    <measurement group_id="O2" value="-0.9" spread="1.0"/>
                    <measurement group_id="O3" value="-1.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fears- Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.1"/>
                    <measurement group_id="O2" value="1.2" spread="1.0"/>
                    <measurement group_id="O3" value="1.0" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fears- Week 2- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.9"/>
                    <measurement group_id="O2" value="-0.4" spread="0.8"/>
                    <measurement group_id="O3" value="-0.2" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fears- Week 4- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.9"/>
                    <measurement group_id="O2" value="-0.5" spread="0.9"/>
                    <measurement group_id="O3" value="-0.3" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fears- Week 6- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.0"/>
                    <measurement group_id="O2" value="-0.5" spread="0.9"/>
                    <measurement group_id="O3" value="-0.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fears- Week 8- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.9"/>
                    <measurement group_id="O2" value="-0.7" spread="1.0"/>
                    <measurement group_id="O3" value="-0.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia- Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.7"/>
                    <measurement group_id="O2" value="2.5" spread="0.7"/>
                    <measurement group_id="O3" value="2.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia- Week 2- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.9"/>
                    <measurement group_id="O2" value="-0.5" spread="1.0"/>
                    <measurement group_id="O3" value="-0.8" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia- Week 4- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.1"/>
                    <measurement group_id="O2" value="-0.8" spread="1.0"/>
                    <measurement group_id="O3" value="-0.9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia- Week 6- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.0"/>
                    <measurement group_id="O2" value="-0.8" spread="1.0"/>
                    <measurement group_id="O3" value="-0.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>insomnia- Week 8- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.1"/>
                    <measurement group_id="O2" value="-0.8" spread="1.0"/>
                    <measurement group_id="O3" value="-1.0" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intellectual- Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.8"/>
                    <measurement group_id="O2" value="2.1" spread="0.8"/>
                    <measurement group_id="O3" value="2.2" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intellectual- Week 2- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.9"/>
                    <measurement group_id="O2" value="-0.4" spread="0.9"/>
                    <measurement group_id="O3" value="-0.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intellectual- Week 4- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.0"/>
                    <measurement group_id="O2" value="-0.6" spread="0.9"/>
                    <measurement group_id="O3" value="-0.7" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intellectual- Week 6- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.1"/>
                    <measurement group_id="O2" value="-0.7" spread="1.0"/>
                    <measurement group_id="O3" value="-0.8" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intellectual- Week 8- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.1"/>
                    <measurement group_id="O2" value="-0.8" spread="1.1"/>
                    <measurement group_id="O3" value="-0.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depressed Mood- Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.8"/>
                    <measurement group_id="O2" value="1.2" spread="0.7"/>
                    <measurement group_id="O3" value="1.0" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depressed Mood- Week 2- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.8"/>
                    <measurement group_id="O2" value="-0.2" spread="0.8"/>
                    <measurement group_id="O3" value="-0.2" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depressed Mood- Week 4- Change in baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.9"/>
                    <measurement group_id="O2" value="-0.3" spread="0.9"/>
                    <measurement group_id="O3" value="-0.3" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depressed Mood- Week 6- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.9"/>
                    <measurement group_id="O2" value="-0.3" spread="0.9"/>
                    <measurement group_id="O3" value="-0.3" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depressed Mood- Week 8- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.9"/>
                    <measurement group_id="O2" value="-0.4" spread="0.9"/>
                    <measurement group_id="O3" value="-0.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic Complaints-Muscular-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.8"/>
                    <measurement group_id="O2" value="1.9" spread="0.8"/>
                    <measurement group_id="O3" value="1.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic Complaints-Muscular-Wk 2-Chg from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.0"/>
                    <measurement group_id="O2" value="-0.3" spread="0.8"/>
                    <measurement group_id="O3" value="-0.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic Complaints-Muscular-Wk 4-Chg from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.9"/>
                    <measurement group_id="O2" value="-0.5" spread="1.0"/>
                    <measurement group_id="O3" value="-0.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic Complaints-Muscular-Wk 6-Chg from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.1"/>
                    <measurement group_id="O2" value="-0.7" spread="1.1"/>
                    <measurement group_id="O3" value="-0.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic Complaints-Muscular-Wk 8-Chg from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.1"/>
                    <measurement group_id="O2" value="-0.7" spread="1.1"/>
                    <measurement group_id="O3" value="-0.7" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic Complaints-Sensory-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.9"/>
                    <measurement group_id="O2" value="1.0" spread="0.9"/>
                    <measurement group_id="O3" value="1.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic Complaints-Sensory-Wk 2-Chg from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.9"/>
                    <measurement group_id="O2" value="-0.2" spread="0.8"/>
                    <measurement group_id="O3" value="-0.5" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic Complaints-Sensory-Wk 4-Chg from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.9"/>
                    <measurement group_id="O2" value="-0.3" spread="1.0"/>
                    <measurement group_id="O3" value="1.0" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic Complaints-Sensory-Wk 6-Chg from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.9"/>
                    <measurement group_id="O2" value="-0.4" spread="0.9"/>
                    <measurement group_id="O3" value="-0.5" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatic Complaints-Sensory-Wk 8-Chg from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.0"/>
                    <measurement group_id="O2" value="-0.4" spread="1.0"/>
                    <measurement group_id="O3" value="-0.5" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular symptoms-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.0"/>
                    <measurement group_id="O2" value="1.2" spread="1.0"/>
                    <measurement group_id="O3" value="1.3" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular symptoms-Wk 2-Chg. from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.0"/>
                    <measurement group_id="O2" value="-0.4" spread="0.9"/>
                    <measurement group_id="O3" value="-0.5" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular symptoms-Wk 4-Chg. from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.0"/>
                    <measurement group_id="O2" value="-0.7" spread="1.0"/>
                    <measurement group_id="O3" value="-0.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular symptoms-Wk 6-Chg. from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.0"/>
                    <measurement group_id="O2" value="-0.6" spread="1.0"/>
                    <measurement group_id="O3" value="-0.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular symptoms-Wk 8-Chg. from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.0"/>
                    <measurement group_id="O2" value="-0.8" spread="1.0"/>
                    <measurement group_id="O3" value="-0.7" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory Symptoms-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.9"/>
                    <measurement group_id="O2" value="1.2" spread="0.9"/>
                    <measurement group_id="O3" value="1.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory Symptoms-Wk 2 Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.9"/>
                    <measurement group_id="O2" value="-0.3" spread="0.8"/>
                    <measurement group_id="O3" value="-0.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory Symptoms-Wk 4 Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.9"/>
                    <measurement group_id="O2" value="-0.5" spread="0.9"/>
                    <measurement group_id="O3" value="-0.5" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory Symptoms-Wk 6 Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.9"/>
                    <measurement group_id="O2" value="-0.5" spread="1.0"/>
                    <measurement group_id="O3" value="-0.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory Symptoms-Wk 8 Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.9"/>
                    <measurement group_id="O2" value="-0.6" spread="0.9"/>
                    <measurement group_id="O3" value="-0.7" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal Symptoms- Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.0"/>
                    <measurement group_id="O2" value="1.4" spread="1.0"/>
                    <measurement group_id="O3" value="1.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal Symptoms-Wk2-Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.1"/>
                    <measurement group_id="O2" value="-0.4" spread="1.0"/>
                    <measurement group_id="O3" value="-0.3" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal Symptoms-Wk4-Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.0"/>
                    <measurement group_id="O2" value="-0.5" spread="1.0"/>
                    <measurement group_id="O3" value="-0.4" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal Symptoms-Wk6-Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.0"/>
                    <measurement group_id="O2" value="-0.6" spread="1.0"/>
                    <measurement group_id="O3" value="-0.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal Symptoms-Wk8-Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.0"/>
                    <measurement group_id="O2" value="-0.6" spread="1.0"/>
                    <measurement group_id="O3" value="-0.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genitourinary Symptoms-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.0"/>
                    <measurement group_id="O2" value="1.4" spread="1.0"/>
                    <measurement group_id="O3" value="1.4" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genitourinary Symptoms-Wk 2-Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.0"/>
                    <measurement group_id="O2" value="-0.2" spread="1.0"/>
                    <measurement group_id="O3" value="-0.3" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genitourinary Symptoms-Wk 4-Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.1"/>
                    <measurement group_id="O2" value="-0.4" spread="1.1"/>
                    <measurement group_id="O3" value="-0.4" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genitourinary Symptoms-Wk 6-Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.1"/>
                    <measurement group_id="O2" value="-0.4" spread="1.1"/>
                    <measurement group_id="O3" value="-0.3" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genitourinary Symptoms-Wk 8-Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.1"/>
                    <measurement group_id="O2" value="-0.5" spread="1.1"/>
                    <measurement group_id="O3" value="-0.4" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autonomic Symptoms-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.9"/>
                    <measurement group_id="O2" value="1.8" spread="0.8"/>
                    <measurement group_id="O3" value="1.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autonomic Symptoms-Wk 2-Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.9"/>
                    <measurement group_id="O2" value="-0.3" spread="0.9"/>
                    <measurement group_id="O3" value="-0.4" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autonomic Symptoms-Wk 4-Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.0"/>
                    <measurement group_id="O2" value="-0.5" spread="1.2"/>
                    <measurement group_id="O3" value="-0.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autonomic Symptoms-Wk 6-Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.0"/>
                    <measurement group_id="O2" value="-0.6" spread="1.1"/>
                    <measurement group_id="O3" value="-0.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autonomic Symptoms-Wk 8-Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.1"/>
                    <measurement group_id="O2" value="-0.7" spread="1.2"/>
                    <measurement group_id="O3" value="-0.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Behavior at Interview-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.7"/>
                    <measurement group_id="O2" value="1.8" spread="0.6"/>
                    <measurement group_id="O3" value="1.8" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Behavior at Interview-Wk 2- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.8"/>
                    <measurement group_id="O2" value="-0.3" spread="0.7"/>
                    <measurement group_id="O3" value="-0.4" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Behavior at Interview-Wk 4- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.7"/>
                    <measurement group_id="O2" value="-0.6" spread="0.8"/>
                    <measurement group_id="O3" value="-0.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Behavior at Interview-Wk 6- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.8"/>
                    <measurement group_id="O2" value="-0.7" spread="0.8"/>
                    <measurement group_id="O3" value="-0.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Behavior at Interview-Wk 8- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.8"/>
                    <measurement group_id="O2" value="-0.6" spread="0.9"/>
                    <measurement group_id="O3" value="-0.7" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinician Global Impression of Severity (CGI-S)</title>
        <description>The CGI-Swas completed by a board certified psychiatrist and represents the clinician's subjective assessment of severity of the subject's anxiety symptoms as assessed by a 7-scale score for a single question, &quot;Considering your total clinical experience with this particular population, how anxious is the subject at this time?&quot; The score was based on the following scale: 1=normal, not at all anxious; 2=borderline anxious; 3=mildly anxious; 4=moderately anxious; 5=markedly anxious; 6=severly anxious; 7=among the most extremely anxious subjects. CGI-S score can range from 0 to 7, with higher values indicating higher severity.</description>
        <time_frame>Baseline, Weeks 2, 4, 6, 8, based on last observation carried forward (LOCF)</time_frame>
        <population>ITT Population: The ITT population will include all randomized subjects who received at least one dose of study medication during the double-blind period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone Low Dose Arm</title>
            <description>SEP-225441 (eszopiclone) total daily dose of 0.9 mg</description>
          </group>
          <group group_id="O3">
            <title>Eszopiclone High Dose Arm</title>
            <description>SEP-225441 (eszopiclone) total daily dose of 1.5 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinician Global Impression of Severity (CGI-S)</title>
          <description>The CGI-Swas completed by a board certified psychiatrist and represents the clinician's subjective assessment of severity of the subject's anxiety symptoms as assessed by a 7-scale score for a single question, &quot;Considering your total clinical experience with this particular population, how anxious is the subject at this time?&quot; The score was based on the following scale: 1=normal, not at all anxious; 2=borderline anxious; 3=mildly anxious; 4=moderately anxious; 5=markedly anxious; 6=severly anxious; 7=among the most extremely anxious subjects. CGI-S score can range from 0 to 7, with higher values indicating higher severity.</description>
          <population>ITT Population: The ITT population will include all randomized subjects who received at least one dose of study medication during the double-blind period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="0.5"/>
                    <measurement group_id="O2" value="4.3" spread="0.5"/>
                    <measurement group_id="O3" value="4.4" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 - Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.9"/>
                    <measurement group_id="O2" value="-0.4" spread="0.6"/>
                    <measurement group_id="O3" value="-0.7" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.9"/>
                    <measurement group_id="O2" value="-0.8" spread="0.8"/>
                    <measurement group_id="O3" value="-1.0" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="1.0"/>
                    <measurement group_id="O2" value="-1.0" spread="1.0"/>
                    <measurement group_id="O3" value="-1.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="1.1"/>
                    <measurement group_id="O2" value="-1.2" spread="1.1"/>
                    <measurement group_id="O3" value="-1.3" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression- Improvement (CGI-I)</title>
        <description>CGI-I was completed by a board certified psychiatrist and represented the clinician's subjective assessment of improvement of the subject's anxiety symptoms based on the following question, &quot;Compared to his/her condition at Visit 2, how much has he/she changed?&quot; The score was based on the following scale: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse. CGI-I score can range from 0 to 7, with higher values indicating less improvement.</description>
        <time_frame>Weeks 2, 4, 6, 8, and 9, based on last observation carried forward (LOCF)</time_frame>
        <population>ITT Population: The ITT population will include all randomized subjects who received at least one dose of study medication during the double-blind period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone Low Dose Arm</title>
            <description>SEP-225441 (eszopiclone) total daily dose of 0.9 mg</description>
          </group>
          <group group_id="O3">
            <title>Eszopiclone High Dose Arm</title>
            <description>SEP-225441 (eszopiclone) total daily dose of 1.5 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression- Improvement (CGI-I)</title>
          <description>CGI-I was completed by a board certified psychiatrist and represented the clinician's subjective assessment of improvement of the subject's anxiety symptoms based on the following question, &quot;Compared to his/her condition at Visit 2, how much has he/she changed?&quot; The score was based on the following scale: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse. CGI-I score can range from 0 to 7, with higher values indicating less improvement.</description>
          <population>ITT Population: The ITT population will include all randomized subjects who received at least one dose of study medication during the double-blind period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="1.0"/>
                    <measurement group_id="O2" value="3.2" spread="0.9"/>
                    <measurement group_id="O3" value="3.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="1.0"/>
                    <measurement group_id="O2" value="2.9" spread="0.9"/>
                    <measurement group_id="O3" value="2.7" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.0"/>
                    <measurement group_id="O2" value="2.6" spread="1.1"/>
                    <measurement group_id="O3" value="2.7" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.1"/>
                    <measurement group_id="O2" value="2.6" spread="1.1"/>
                    <measurement group_id="O3" value="2.6" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.1"/>
                    <measurement group_id="O2" value="2.5" spread="1.1"/>
                    <measurement group_id="O3" value="2.4" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hamilton Anxiety Scale (HAM-A) 50% Anxiolytic Response</title>
        <description>The HAM-A was administered by a site-trained rater and measured the severity of the subjects' anxiety symptoms using 14 items of the HAM-A rating scale. These items include: anxious mood, tension, fears, insomnia, intellectual, depressed mood, somatic complaints-muscular, somatic complaints-sensory, cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary symptoms, autonomic symptoms, and behavior at interview. All items are measured on a 5-point scale (0-4). A 50% anxiolytic response was defined as a 50% or greater reduction from baseline in the HAM-A total score.
The Ham-A total score can range from 0 to 56 with higher scores indicating higher severity of anxiety symptoms.</description>
        <time_frame>Week 2, 4, 6, 8</time_frame>
        <population>ITT Population: The ITT population will include all randomized subjects who received at least one dose of study medication during the double-blind period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone Low Dose Arm</title>
            <description>SEP-225441 (eszopiclone) total daily dose of 0.9 mg</description>
          </group>
          <group group_id="O3">
            <title>Eszopiclone High Dose Arm</title>
            <description>SEP-225441 (eszopiclone) total daily dose of 1.5 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Anxiety Scale (HAM-A) 50% Anxiolytic Response</title>
          <description>The HAM-A was administered by a site-trained rater and measured the severity of the subjects' anxiety symptoms using 14 items of the HAM-A rating scale. These items include: anxious mood, tension, fears, insomnia, intellectual, depressed mood, somatic complaints-muscular, somatic complaints-sensory, cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary symptoms, autonomic symptoms, and behavior at interview. All items are measured on a 5-point scale (0-4). A 50% anxiolytic response was defined as a 50% or greater reduction from baseline in the HAM-A total score.
The Ham-A total score can range from 0 to 56 with higher scores indicating higher severity of anxiety symptoms.</description>
          <population>ITT Population: The ITT population will include all randomized subjects who received at least one dose of study medication during the double-blind period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hamilton Anxiety Scale (HAM-A) Remission</title>
        <description>The HAM-A was administered by a site-trained rater and measured the severity of the subjects' anxiety symptoms using 14 items of the HAM-A rating scale. These items include: anxious mood, tension, fears, insomnia, intellectual, depressed mood, somatic complaints-muscular, somatic complaints-sensory, cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary symptoms, autonomic symptoms, and behavior at interview. All items are measured on a 5-point scale (0-4). Remission was defined as a HAM-A total score of 7 or less.
The Ham-A total score can range from 0 to 56 with higher scores indicating higher severity of anxiety symptoms.</description>
        <time_frame>Week 2, 4, 6, 8 based on last observation carried forward (LOCF)</time_frame>
        <population>ITT Population: The ITT population will include all randomized subjects who received at least one dose of study medication during the double-blind period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone Low Dose Arm</title>
            <description>SEP-225441 (eszopiclone) total daily dose of 0.9 mg</description>
          </group>
          <group group_id="O3">
            <title>Eszopiclone High Dose Arm</title>
            <description>SEP-225441 (eszopiclone) total daily dose of 1.5 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Anxiety Scale (HAM-A) Remission</title>
          <description>The HAM-A was administered by a site-trained rater and measured the severity of the subjects' anxiety symptoms using 14 items of the HAM-A rating scale. These items include: anxious mood, tension, fears, insomnia, intellectual, depressed mood, somatic complaints-muscular, somatic complaints-sensory, cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary symptoms, autonomic symptoms, and behavior at interview. All items are measured on a 5-point scale (0-4). Remission was defined as a HAM-A total score of 7 or less.
The Ham-A total score can range from 0 to 56 with higher scores indicating higher severity of anxiety symptoms.</description>
          <population>ITT Population: The ITT population will include all randomized subjects who received at least one dose of study medication during the double-blind period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Short Form</title>
        <description>The Q-LES-Q was completed by the subject and assessed quaility of life based on 16 items, each evaluated on a 5-point scale of overall level of enjoyment/satisfaction: 1=very poor; 2=poor; 3=fair; 4=good; 5=very good. The overall percentage score was computed as a sum of items 1 to 14 as expressed as a percentage of the maximum possible score: Overall Percentage Score = Sum [item 1... item 14]-14)/(70-14 ) *100%. Q-LES-Q overall percentage score can range from 0 to 100, with higher values indicating higher quality of life.</description>
        <time_frame>Baseline, Weeks 2, 4, 6, 8, based on last observation carried forward (LOCF)</time_frame>
        <population>ITT Population: The ITT population will include all randomized subjects who received at least one dose of study medication during the double-blind period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone Low Dose Arm</title>
            <description>SEP-225441 (eszopiclone) total daily dose of 0.9 mg</description>
          </group>
          <group group_id="O3">
            <title>Eszopiclone High Dose Arm</title>
            <description>SEP-225441 (eszopiclone) total daily dose of 1.5 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Short Form</title>
          <description>The Q-LES-Q was completed by the subject and assessed quaility of life based on 16 items, each evaluated on a 5-point scale of overall level of enjoyment/satisfaction: 1=very poor; 2=poor; 3=fair; 4=good; 5=very good. The overall percentage score was computed as a sum of items 1 to 14 as expressed as a percentage of the maximum possible score: Overall Percentage Score = Sum [item 1... item 14]-14)/(70-14 ) *100%. Q-LES-Q overall percentage score can range from 0 to 100, with higher values indicating higher quality of life.</description>
          <population>ITT Population: The ITT population will include all randomized subjects who received at least one dose of study medication during the double-blind period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" spread="14.9"/>
                    <measurement group_id="O2" value="52.2" spread="13.5"/>
                    <measurement group_id="O3" value="52.0" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="10.6"/>
                    <measurement group_id="O2" value="2.1" spread="13.2"/>
                    <measurement group_id="O3" value="1.5" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="12.4"/>
                    <measurement group_id="O2" value="5.4" spread="12.7"/>
                    <measurement group_id="O3" value="4.6" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="13.7"/>
                    <measurement group_id="O2" value="6.7" spread="13.4"/>
                    <measurement group_id="O3" value="5.0" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="14.8"/>
                    <measurement group_id="O2" value="6.8" spread="13.2"/>
                    <measurement group_id="O3" value="5.8" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Insomnia Severity Index (ISI) Total Score</title>
        <description>The ISI was completed by the subject and is an assessment of the severity of insomnia. The administered extended ISI questionnaire consists of 5 items (containing 7 questions, as item 1 contains 3 questions) comprising the original ISI questionnaire, plus 6 quality of life related items (sleep quality, restedness/refreshness upon arising, daytime fatigue, attention/concentration, relationships and mood disturbances), and 2 items assessing duration and frequency of sleep problems. All items, except for the insomnia duration and frequency questions, are measured on a Likert-type 5-point scale (0-4). ISI total score can range from 0 to 28, with higher scores indicating more severe insomnia.</description>
        <time_frame>Baseline, Weeks 2, 4, 6, 8, based on lst observation carried forward (LOCF)</time_frame>
        <population>ITT Population: The ITT population will include all randomized subjects who received at least one dose of study medication during the double-blind period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone Low Dose Arm</title>
            <description>SEP-225441 (eszopiclone) total daily dose of 0.9 mg</description>
          </group>
          <group group_id="O3">
            <title>Eszopiclone High Dose Arm</title>
            <description>SEP-225441 (eszopiclone) total daily dose of 1.5 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Insomnia Severity Index (ISI) Total Score</title>
          <description>The ISI was completed by the subject and is an assessment of the severity of insomnia. The administered extended ISI questionnaire consists of 5 items (containing 7 questions, as item 1 contains 3 questions) comprising the original ISI questionnaire, plus 6 quality of life related items (sleep quality, restedness/refreshness upon arising, daytime fatigue, attention/concentration, relationships and mood disturbances), and 2 items assessing duration and frequency of sleep problems. All items, except for the insomnia duration and frequency questions, are measured on a Likert-type 5-point scale (0-4). ISI total score can range from 0 to 28, with higher scores indicating more severe insomnia.</description>
          <population>ITT Population: The ITT population will include all randomized subjects who received at least one dose of study medication during the double-blind period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" spread="5.3"/>
                    <measurement group_id="O2" value="14.3" spread="5.3"/>
                    <measurement group_id="O3" value="14.1" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="4.4"/>
                    <measurement group_id="O2" value="-1.5" spread="5.0"/>
                    <measurement group_id="O3" value="-2.7" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="4.8"/>
                    <measurement group_id="O2" value="-3.1" spread="5.4"/>
                    <measurement group_id="O3" value="-3.4" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="5.6"/>
                    <measurement group_id="O2" value="-3.6" spread="5.5"/>
                    <measurement group_id="O3" value="-3.6" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="5.6"/>
                    <measurement group_id="O2" value="-3.5" spread="6.2"/>
                    <measurement group_id="O3" value="-4.1" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Sheehan Disability Scale (SDS)</title>
        <description>The SDS was completed by the subject and captured the subjects level of disability. The subject rated the extent to which his or her work, social life or leisure activities, and home life or family responsibilities were impaired by his or her symptoms on a 10-point visual analog scale. SDS total score can range from 0 to 30, with higher scores indicating higher functional impairment.</description>
        <time_frame>Baseline, Weeks 2, 4, 6, 8, based on last observation carried forward (LOCF)</time_frame>
        <population>ITT Population: The ITT population will include all randomized subjects who received at least one dose of study medication during the double-blind period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone Low Dose Arm</title>
            <description>SEP-225441 (eszopiclone) total daily dose of 0.9 mg</description>
          </group>
          <group group_id="O3">
            <title>Eszopiclone High Dose Arm</title>
            <description>SEP-225441 (eszopiclone) total daily dose of 1.5 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Sheehan Disability Scale (SDS)</title>
          <description>The SDS was completed by the subject and captured the subjects level of disability. The subject rated the extent to which his or her work, social life or leisure activities, and home life or family responsibilities were impaired by his or her symptoms on a 10-point visual analog scale. SDS total score can range from 0 to 30, with higher scores indicating higher functional impairment.</description>
          <population>ITT Population: The ITT population will include all randomized subjects who received at least one dose of study medication during the double-blind period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" spread="6.7"/>
                    <measurement group_id="O2" value="14.0" spread="6.4"/>
                    <measurement group_id="O3" value="14.8" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="5.5"/>
                    <measurement group_id="O2" value="-0.9" spread="6.3"/>
                    <measurement group_id="O3" value="-2.7" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="6.1"/>
                    <measurement group_id="O2" value="-2.5" spread="6.3"/>
                    <measurement group_id="O3" value="-3.5" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="6.5"/>
                    <measurement group_id="O2" value="-3.4" spread="6.3"/>
                    <measurement group_id="O3" value="-4.1" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="6.6"/>
                    <measurement group_id="O2" value="-4.1" spread="6.5"/>
                    <measurement group_id="O3" value="-4.4" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Epworth Sleepiness Scale (ESS)</title>
        <description>ESS was completed by the subject and assessed daytime sedation based on 8 items, each presenting a situation for which the subject needed to evaluate how likely he/she is to doze off or fall asleep in contrast to feeling just tired. Each item was evaluated on the following scale: 0 = would never doze; 1 = slight chance of dozing; 2 = moderate chance of dozing; 3 = high chance of dozing. ESS total score can range from 0 to 24, with higher scores indicating higher levels of daytime sleepiness.</description>
        <time_frame>Baseline, Weeks 2, 4, 6, 8, based on last observation carried forward (LOCF)</time_frame>
        <population>ITT Population: The ITT population will include all randomized subjects who received at least one dose of study medication during the double-blind period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Eszopiclone Low Dose Arm</title>
            <description>SEP-225441 (eszopiclone) total daily dose of 0.9 mg</description>
          </group>
          <group group_id="O3">
            <title>Eszopiclone High Dose Arm</title>
            <description>SEP-225441 (eszopiclone) total daily dose of 1.5 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Epworth Sleepiness Scale (ESS)</title>
          <description>ESS was completed by the subject and assessed daytime sedation based on 8 items, each presenting a situation for which the subject needed to evaluate how likely he/she is to doze off or fall asleep in contrast to feeling just tired. Each item was evaluated on the following scale: 0 = would never doze; 1 = slight chance of dozing; 2 = moderate chance of dozing; 3 = high chance of dozing. ESS total score can range from 0 to 24, with higher scores indicating higher levels of daytime sleepiness.</description>
          <population>ITT Population: The ITT population will include all randomized subjects who received at least one dose of study medication during the double-blind period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="4.5"/>
                    <measurement group_id="O2" value="8.4" spread="4.5"/>
                    <measurement group_id="O3" value="8.5" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="4.0"/>
                    <measurement group_id="O2" value="-0.5" spread="3.8"/>
                    <measurement group_id="O3" value="-0.4" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="4.6"/>
                    <measurement group_id="O2" value="-1.0" spread="4.1"/>
                    <measurement group_id="O3" value="-0.7" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="4.0"/>
                    <measurement group_id="O2" value="-1.3" spread="4.0"/>
                    <measurement group_id="O3" value="-0.9" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8- Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="4.0"/>
                    <measurement group_id="O2" value="-1.4" spread="4.2"/>
                    <measurement group_id="O3" value="-1.3" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Arm</title>
          <description>Placebo</description>
        </group>
        <group group_id="E2">
          <title>Eszopiclone Low Dose Arm</title>
          <description>SEP-225441 (eszopiclone) total daily dose of 0.9 mg</description>
        </group>
        <group group_id="E3">
          <title>Eszopiclone High Dose Arm</title>
          <description>SEP-225441 (eszopiclone) total daily dose of 1.5 mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Amniotic Cavity Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Traumatic Brain Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Self Injurious Behavior</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="146"/>
                <counts group_id="E3" subjects_affected="116" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="14" subjects_at_risk="149"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="146"/>
                <counts group_id="E3" events="21" subjects_affected="18" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="149"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="146"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="149"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="146"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="149"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="146"/>
                <counts group_id="E3" events="20" subjects_affected="14" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="149"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="146"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="149"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="146"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Nasaopharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="149"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="146"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="146"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="47" subjects_affected="27" subjects_at_risk="149"/>
                <counts group_id="E2" events="44" subjects_affected="26" subjects_at_risk="146"/>
                <counts group_id="E3" events="41" subjects_affected="24" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E2" events="16" subjects_affected="10" subjects_at_risk="146"/>
                <counts group_id="E3" events="37" subjects_affected="35" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="149"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="146"/>
                <counts group_id="E3" events="20" subjects_affected="16" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="149"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="146"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="146"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eszopiclone Medical Director</name_or_title>
      <organization>Sunovion</organization>
      <phone>866-503-7813</phone>
      <email>clinicaltrialdisclosure@sunovion.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

